Amman, May 18 (Petra) — Regional pharmaceutical leader MS Pharma on
Monday announced it has secured a strategic investment from Olayan
Financing Company, which acquired a minority stake in the firm to
accelerate growth and expansion plans across Saudi Arabia and the
Middle East and North Africa (MENA) region.

According to a corporate statement, the transaction involves the
issuance of new shares in exchange for a cash injection from Olayan
Financing Company. The capital will strengthen MS Pharma’s financial
and operational capabilities, backing its strategic roadmap to expand
its portfolio of generic and biosimilar medicines while scaling up
its manufacturing and supply capacity.

The partnership marks a new phase in the company’s trajectory,
reflecting its commitment to investing in innovation, widening its
regional footprint, and creating sustainable, long-term value.

MS Pharma Chairman Ghiath Sukhtian stated that the partnership with
Olayan Financing Company represents a qualitative addition for the
firm, given the group’s extensive investment and operational
expertise alongside its deep-rooted presence in the Saudi market. He
added that the investment underscores MS Pharma’s positioning as a
leading regional pharmaceutical corporation.

MS Pharma Chief Executive Officer Kalle Känd noted that the
investment arrives at a pivotal juncture in the company’s growth. He
emphasized that it will bolster the firm’s expertise in the
biopharmaceutical sector, accelerate its expansion across Saudi
Arabia and the wider region, and drive its strategic roadmap within
the biosimilars segment.

Nabeel Al Amudi, Chief Executive Officer of Olayan Financing Company,
commented that MS Pharma has successfully built a robust
pharmaceutical platform in the region with advanced capabilities in
generics and biologics. He expressed the group’s commitment to
supporting MS Pharma’s expansion in alignment with Olayan’s long-term
investment philosophy.

The statement highlighted MS Pharma’s ongoing efforts to reinforce
its presence in the biologics sector. Its biopharmaceutical plant in
Saudi Arabia has become the first facility in the Kingdom to receive
Good Manufacturing Practice (GMP) certification from the Saudi Food
and Drug Authority (SFDA) for biologics manufacturing. The company
plans to become the first local supplier of domestically manufactured
biopharmaceuticals to the Saudi market during the current year.

The pharmaceutical firm confirmed that these milestones support
localization targets outlined within Saudi Arabia’s National
Biotechnology Strategy and Vision 2030, while simultaneously
improving access to high-quality biological treatments across the
region.

MS Pharma operates as a prominent regional pharmaceutical
manufacturer in the MENA market, running five manufacturing
facilities across Jordan, Algeria, and Saudi Arabia and employing a
workforce of over 2,000 personnel spread across 12 countries.

//Petra// AF